Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.61 |
| ▸ | THRA | P10827 | 9/20 | 0.61 |
| ▸ | THRB | P10828 | 9/20 | 0.61 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | ASPH | Q12797 | 1/20 | 0.50 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409796 | 0.87 | EGLN1 (0.64) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL522602 | 0.83 | EGLN1 (0.78) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL4417170 | 0.83 | THRA (0.70) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL5318629 | 0.80 | EGLN1 (0.66) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL3924454 | 0.78 | EGLN1 (0.65) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL523521 | 0.76 | THRA (0.91) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL522940 | 0.76 | THRA (1.00) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL4411746 | 0.75 | EGLN1 (0.61) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL1841936 | 0.75 | EGLN1 (0.56) | EGLN1THRATHRBBBOX1FTO | |
| SCHEMBL5325511 | 0.75 | EGLN1 (0.61) | EGLN1THRATHRBBBOX1FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009002533-A1 | INFLAMMATORY BOWEL DISEASE THERAPIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| EP-1919463-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007146425-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA | FIBROGEN, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2006138511-A2 | USE OF HIF 1ALFA MODULATORS FOR TREATMENT OF CANCER | FIBROGEN, INC. (US) | 2006-12-28 | — | — | WO | disclosed |